SCHEMBL4898155

SCHEMBL4898155

N#Cc1c(O)ncnc1-c1cccc([N+](=O)[O-])c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 1/20 0.45
WDR5 P61964 1/20 0.45
PDE4D Q08499 5/20 0.44
ALDH1A1 P00352 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TSHR P16473 2/20 0.42
ALOX15 P16050 1/20 0.42
PDE4A P27815 3/20 0.41
PDE4C Q08493 3/20 0.41
PDE4B Q07343 1/20 0.41
PIK3CA P42336 2/20 0.40
PIK3CG P48736 2/20 0.40
IDO1 P14902 1/20 0.40
PIK3CD O00329 1/20 0.40
PIK3CB P42338 1/20 0.40
PRKDC P78527 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4904156 0.85 PDE4D (0.47) MYCWDR5PDE4DALDH1A1NPC1
SCHEMBL4421556 0.79 NPC1 (0.49) MYCWDR5PDE4DALDH1A1NPC1
SCHEMBL4908034 0.78 BACE1 (0.47) MYCWDR5ALDH1A1NPC1RAB9A
SCHEMBL4427518 0.77 MYC (0.46) MYCWDR5PDE4DALDH1A1NPC1
SCHEMBL5026966 0.76 NPC1 (0.52) MYCWDR5PDE4DNPC1RAB9A
SCHEMBL14501793 0.76 PARP1 (0.45) MYCWDR5PDE4DALDH1A1NPC1
SCHEMBL5026125 0.74 MAPT (0.52) MYCWDR5ALDH1A1NPC1RAB9A
SCHEMBL5024681 0.74 NPC1 (0.53) MYCWDR5PDE4DALDH1A1NPC1
SCHEMBL4898242 0.74 CTSL (0.50) MYCWDR5PDE4DPDE4APDE4C
SCHEMBL12679739 0.73 TSHR (0.52) ALDH1A1NPC1RAB9AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF MYC 2402/4885WDR5 3131/4885PDE4D 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.